| Primary |
| Rhinitis Allergic |
16.2% |
| Urticaria |
14.5% |
| Hypersensitivity |
14.0% |
| Hypertension |
8.4% |
| Eczema |
5.1% |
| Seasonal Allergy |
4.9% |
| Multiple Allergies |
4.5% |
| Dermatitis Atopic |
3.5% |
| Insomnia |
3.4% |
| Sinusitis |
3.4% |
| Product Used For Unknown Indication |
3.2% |
| Asthma |
2.4% |
| Pruritus |
2.4% |
| Rhinitis |
2.2% |
| Depression |
2.0% |
| Drug Use For Unknown Indication |
2.0% |
| Gastritis |
2.0% |
| Laryngopharyngitis |
2.0% |
| Nasal Congestion |
2.0% |
| Rash |
2.0% |
|
| Liver Disorder |
12.0% |
| Loss Of Consciousness |
9.9% |
| Malaise |
9.1% |
| Hepatic Function Abnormal |
8.0% |
| Vomiting |
6.2% |
| Atrial Fibrillation |
5.1% |
| Drug Ineffective |
4.7% |
| Extra Dose Administered |
4.7% |
| White Blood Cell Count Decreased |
4.4% |
| Stevens-johnson Syndrome |
4.0% |
| Weight Increased |
4.0% |
| Headache |
3.3% |
| Palpitations |
3.3% |
| Somnolence |
3.3% |
| Urinary Retention |
3.3% |
| Convulsion |
2.9% |
| Electrocardiogram Qt Prolonged |
2.9% |
| Jaundice |
2.9% |
| Nausea |
2.9% |
| Rhabdomyolysis |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
12.4% |
| Drug Use For Unknown Indication |
12.0% |
| Urticaria |
10.4% |
| Dermatitis Allergic |
8.6% |
| Hypersensitivity |
7.8% |
| Hyperthyroidism |
7.2% |
| Hypertension |
6.5% |
| Rhinitis Allergic |
4.5% |
| Asthma |
4.3% |
| Sinusitis |
3.9% |
| Multiple Allergies |
3.1% |
| Pruritus |
3.1% |
| Seasonal Allergy |
2.5% |
| Insomnia |
2.3% |
| Constipation |
2.0% |
| Pain |
2.0% |
| Chronic Sinusitis |
1.9% |
| Depression |
1.9% |
| Hyperlipidaemia |
1.9% |
| Osteoporosis |
1.7% |
|
| Asthenia |
10.5% |
| Hepatitis Fulminant |
10.0% |
| Drug Hypersensitivity |
8.0% |
| Tachycardia |
7.0% |
| Rash |
6.5% |
| Vomiting |
6.5% |
| Urticaria |
6.0% |
| Platelet Count Decreased |
5.0% |
| Loss Of Consciousness |
4.0% |
| Pruritus |
4.0% |
| Vision Blurred |
4.0% |
| Malaise |
3.5% |
| Pyrexia |
3.5% |
| Somnolence |
3.5% |
| Drug Ineffective |
3.0% |
| Dysgeusia |
3.0% |
| Hepatic Function Abnormal |
3.0% |
| Hypotension |
3.0% |
| Leukocytoclastic Vasculitis |
3.0% |
| Liver Disorder |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.2% |
| Drug Use For Unknown Indication |
14.4% |
| Asthma |
7.5% |
| Hypertension |
6.7% |
| Hypersensitivity |
6.2% |
| Prophylaxis |
4.4% |
| Pain |
4.1% |
| Depression |
3.7% |
| Rheumatoid Arthritis |
3.5% |
| Gastrooesophageal Reflux Disease |
3.2% |
| Osteoporosis |
2.7% |
| Hepatitis C |
2.7% |
| Diabetes Mellitus |
2.5% |
| Multiple Allergies |
2.3% |
| Seasonal Allergy |
2.2% |
| Anxiety |
1.9% |
| Insomnia |
1.8% |
| Chronic Hepatitis C |
1.7% |
| Arthritis |
1.7% |
| Premedication |
1.6% |
|
| Vomiting |
12.0% |
| Weight Decreased |
9.2% |
| Weight Increased |
8.9% |
| Nausea |
5.6% |
| Rash |
5.6% |
| Urticaria |
5.5% |
| Pain |
5.3% |
| Drug Ineffective |
5.1% |
| Pulmonary Embolism |
5.1% |
| Pruritus |
4.2% |
| Vision Blurred |
4.0% |
| White Blood Cell Count Decreased |
3.9% |
| Pyrexia |
3.8% |
| Pneumonia |
3.6% |
| Myocardial Infarction |
3.4% |
| Urinary Tract Infection |
3.2% |
| Dyspnoea |
2.9% |
| Sinusitis |
2.9% |
| Tremor |
2.9% |
| Oedema Peripheral |
2.9% |
|
| Interacting |
| Hypersensitivity |
12.8% |
| Depression |
8.5% |
| Back Disorder |
6.4% |
| Back Pain |
6.4% |
| Bladder Obstruction |
6.4% |
| Fibromyalgia |
6.4% |
| Hypertension |
6.4% |
| Irritable Bowel Syndrome |
6.4% |
| Vitamin D Deficiency |
6.4% |
| Blood Cholesterol Increased |
4.3% |
| Blood Pressure High |
4.3% |
| Gastrooesophageal Reflux Disease |
4.3% |
| Product Used For Unknown Indication |
4.3% |
| Seasonal Allergy |
4.3% |
| Acid Reflux (Esophageal) |
2.1% |
| Allergy |
2.1% |
| Headache |
2.1% |
| High Cholesterol |
2.1% |
| Migraine |
2.1% |
| Rhinorrhoea |
2.1% |
|
| Drug Interaction |
23.1% |
| Drug Ineffective |
15.4% |
| Loss Of Consciousness |
15.4% |
| Drug Administration Error |
7.7% |
| Inhibitory Drug Interaction |
7.7% |
| International Normalised Ratio Decreased |
7.7% |
| Psychomotor Hyperactivity |
7.7% |
| Tension |
7.7% |
| Weight Increased |
7.7% |
|
